Biogen finalizes $900M settlement in false claims whistleblower suit
By 
Adrianne Appel2022-09-27T19:04:00
Biogen finalized a $900 million settlement concerning alleged kickbacks it paid to doctors to induce them to prescribe the company’s drugs and not those of its competitors, the Department of Justice (DOJ) announced Monday.
Biogen made the alleged payments to try and dampen competition for its multiple sclerosis (MS) drugs, including Avonex, Tysabri, and Tecfidera, according to the settlement.
The agreement, first disclosed by Biogen in July, ends years of litigation dating back to 2012, when former employee Michael Bawduniak blew the whistle on the alleged kickbacks. He filed a lawsuit against the company in U.S. District Court for the District of Massachusetts, citing violations of the False Claims Act (FCA).
Related articles
-
ArticlePharma, whistleblower lessons learned from $900M Biogen settlement
Experts discuss the ramifications of Biogen’s $900 million settlement for False Claims Act violations, including the $266.4 million whistleblower bounty in the case believed to be the largest single award under any government program.
-
ArticlePhilips to pay $1.3M in second kickback settlement in month
Philips RS North America agreed to pay approximately $1.3 million to settle charges it unlawfully paid kickbacks as part of its second resolution addressing alleged False Claims Act violations this month.
-
ArticleEssilor agrees to $22M settlement over kickback charges
Essilor, a manufacturer and distributor of optical lenses and equipment, will pay $22 million to settle allegations it paid kickbacks to spur sales in violation of the False Claims Act.
More from Regulatory Enforcement
-
ArticleNJ BCBS pays $100M to settle state false claims allegations
Horizon Blue Cross Blue Shield of New Jersey has agreed to pay $100 million to settle allegations that its 2020 contract with the state was fraudulent, according the state’s Attorney General.
-
PremiumA case-by-case analysis of FCPA investigation closures
Foreign corruption enforcement relating to national security matters has been a common theme under the Trump administration. A second common theme continues to be the discrete way in which the DOJ has ended several FCPA investigations.
-
ArticleFinCEN cuts off 10 Mexican casinos from U.S. financial system for laundering cartel drug money
Ten Mexican cartels will be severed from the U.S. financial system for laundering money for the Sinaloa Cartel criminal organization, according to the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN).